Novo Nordisk completes the construction of a wastewater treatment plant in Clayton, North Carolina, which will be donated to the city to aid biopharma growth.
India-headquartered Glenmark Pharmaceuticals has opened a 100,000-square-foot facility on the East Coast for the manufacture of fixed dose formulations.
Pfizer has chosen a site in Sanford, North Carolina for a gene therapy production plant, just 40 miles from its recent acquisition Bamboo Therapeutics Inc.
Unconfirmed reports suggest Laboratory Corporation of America Holdings (LabCorp) is in talks to acquire contract research organization Pharmaceutical Product Development LLC (PPD).
Earlier this week, INC Research announced its intent to expand at its headquarters in Wake County, creating 550 jobs over the next several years as part of a $37.9m investment.
Endo International has signed an agreement to sell its facility in Charlotte, North Carolina to an unnamed buyer that will take on 125 workers currently employed at the site.
Endo International says it intends to expedite a cost-saving plan by closing a manufacturing site in North Carolina and reducing headcount at another in Alabama.
Several US states have approached Braeburn Pharmaceuticals after the firm said it was reassessing plans to invest $20m in North Carolina following the passing of House Bill 2.
Anti-LGBT legislation has prompted Braeburn Pharmaceuticals to reassess plans for a $20m facility in North Carolina, but will others in "the nation’s number one state for biomanufacturing" follow suit?
Mayne Pharma has started adding contract manufacturing capacity at its site in North Carolina in an project that will also see it consolidate US distribution operations.
Anti-infectives firm Xellia has moved its North American HQ to the lyophilisation plant in Raleigh, North Carolina that it bought from Fresenius Kabi last July.
Beginning Sept. 30, Massachusetts-based CRO (contract research organization) Parexel will lay off as many as 125 of the 450 employees it brought on from GlaxoSmithKline (GSK) in North Carolina late last year, according to a North Carolina WARN report...
Hospira’s closure of its manufacturing facility in Clayton, North Carolina, which it says is a cost rather than a quality issue, will result in the laying off of 100 employees, according to a WARN notice posted Wednesday.
Service provider BioClinica will open a Research Triangle Park (RTP) office in North Carolina in response to a rapidly expanding customer base of study sponsors and CROs (contract research organizations) with which it has strategic partnerships.
GlaxoSmithKline is significantly reducing the size of its R&D team in the US, though about 450 of those employees who will be laid off in the Research Triangle Park (RTP), North Carolina area will find new jobs with CRO Parexel.
Xellia has agreed to invest $100m in equipment, retain staff and create 40 full time jobs at the plant it bought in Raleigh, North Carolina in return for business incentives.
Manufacturing problems and costs associated with a new device-focused strategy hurt in Q1, but Hospira says efforts to fix troubled Rocky Mount facility are still on track.
Exela Pharma Sciences will invest $8.5million in its research and manufacturing plant in North Carolina. The venture, to be spread over the next three years, will provide 38 new jobs almost doubling its present workforce.
Hospira hopes to ramp up output at its Rocky Mount facility in the second half of 2012 but warned it is “very difficult” to predict the remediation timeline.
West Pharmaceutical Services will invest $29m to expand its syringe plungers and intravenous (IV) system components facility in Kinston, North Carolina, in the US.
in-PharmaTechnologist.com's periodic round-up of developments in
the field of pharmaceutical facilities includes news of two
environmental fines, MHRA plant approval and a strike at Teva.
Drug maker Merck & Co has entered an expansion phase, to boost
global manufacturing capacity for vaccines, adding $100 million to
its facilities in Durham.
Quintiles has formed a new alliance with a hospital near its
headquarters in North Carolina, from where it has begun running
clinical trials on experimental drugs.
